Recurrent Lung Cancer Clinical Trials
2 recruiting trials for Recurrent Lung Cancer. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Recurrent Lung Cancer clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 1 / Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Alpha Tau Medical LTD. (1), Institut de Recherches Internationales Servier (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) (device, 1 trial), followed by S241656, FOLFOX6/FOLFOX7.
Track Recurrent Lung Cancer trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for treatment of recurrent Lung Cancer .
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Recurrent Lung Cancer, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Recurrent Lung Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Recurrent Lung Cancer, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.